Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin-ESHAP versus ESHAP in relapsed or refractory classical Hodgkin lymphoma
2019-002746-21Phase 2Active
- Sponsor
- Fundación GEL
- Start
- Feb 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Fundación GEL. Primary endpoint: Treatment response based on Deauville scores 1 or 2 at interim PET-CT. Started Feb 2020; status: active.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2019-002746-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002746-21.